Mind Medicine Mindmed Inc (MNMD) Stock Price, Quote & News

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: www.mindmed.co

Address:

One World Trade Center, Suite 8500, New York, United States

MichaelNaussCMT Dec. 17 at 2:48 PM

$MNMD 13 is everything

0 · Reply

BullsVSBearsVSYoMomma Dec. 16 at 7:59 PM

$MNMD Close to breaking above this

1 · Reply

ZacksResearch Dec. 16 at 4:38 PM

High-risk biotech plays that could make—or break—portfolios in 2026 ⚠️🚀 $MNMD and four other biotech disruptors are heading into pivotal studies and FDA decisions in 2026, setting the stage for high-risk, high-reward outcomes that could dramatically reprice these stocks. Bold setups, binary catalysts, and massive upside if the science and regulators align. Discover the five names to watch closely 👉 https://www.zacks.com/stock/news/2804883/5-high-risk-high-reward-biotech-breakthrough-stocks-to-watch-in-2026?cid=sm-stocktwits-2-2804883-teaser-25027&ADID=SYND_STOCKTWITS_TWEET_2_2804883_TEASER_25027

0 · Reply

ZacksResearch Dec. 16 at 3:38 PM

Biotech breakthrough: Why $MNMD could be a 2026 game-changer! 🚀 MNMD's MM120 received breakthrough therapy designation for GAD, with pivotal data readouts expected in 2026. A recent $258.9M financing strengthens its balance sheet for accelerated development. Discover the full potential here 👉 https://www.zacks.com/stock/news/2804883/5-high-risk-high-reward-biotech-breakthrough-stocks-to-watch-in-2026?cid=sm-stocktwits-2-2804883-body-25023&ADID=SYND_STOCKTWITS_TWEET_2_2804883_BODY_25023

0 · Reply

BioBum Dec. 15 at 9:50 PM

$MNMD MindMed inducement grants for new employees happening every week. You’d think that would add up after the 8th or 9th one this year

0 · Reply

Rocketzz Dec. 15 at 6:48 PM

$MNMD smart money is accumulating in this zone

0 · Reply

MoneyGroupLLC Dec. 14 at 8:38 PM

Enter: $MNMD Calls Strike Price: $13 Expiry Date: JAN 16 2026 Buy in Price: $1.00 - $1.15 Sell Price: $2.01 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 12 at 6:42 PM

Enter: $MNMD Calls Strike Price: $13 Expiry Date: JAN 16 2026 Buy in Price: $0.85 - $1.25 Sell Price: $1.52 Profit : +79% (Turn every $1 into $1.79) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

zcurrency Dec. 12 at 1:06 AM

$MNMD

0 · Reply

a_rational_investor Dec. 12 at 12:02 AM

$MNMD typical AH drop for people to load up

0 · Reply

MindMed Announces New Employee Inducement Grant

Dec 1, 2025, 4:01 PM EST - 15 days ago

MindMed Announces New Employee Inducement Grants

Nov 6, 2025, 9:46 PM EST - 5 weeks ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 5 weeks ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 6 weeks ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 6 weeks ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 6 weeks ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 6 weeks ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 6 weeks ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 14, 2025, 12:28 PM EDT - 2 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 13, 2025, 2:54 PM EDT - 2 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 19, 2025, 7:00 AM EDT - 3 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 3 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 3 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 9:48 PM EDT - 4 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:01 PM EDT - 4 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 5 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

May 28, 2025, 7:00 AM EDT - 7 months ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 7 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 13, 2025, 7:00 AM EDT - 7 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 7 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 7 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 8 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 8 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 9 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 10 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 10 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 10 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 10 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 11 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 11 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Aug 9, 2024, 8:44 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

MichaelNaussCMT Dec. 17 at 2:48 PM

$MNMD 13 is everything

0 · Reply

BullsVSBearsVSYoMomma Dec. 16 at 7:59 PM

$MNMD Close to breaking above this

1 · Reply

ZacksResearch Dec. 16 at 4:38 PM

0 · Reply

ZacksResearch Dec. 16 at 3:38 PM

0 · Reply

BioBum Dec. 15 at 9:50 PM

$MNMD MindMed inducement grants for new employees happening every week. You’d think that would add up after the 8th or 9th one this year

0 · Reply

Rocketzz Dec. 15 at 6:48 PM

$MNMD smart money is accumulating in this zone

0 · Reply

MoneyGroupLLC Dec. 14 at 8:38 PM

0 · Reply

MoneyGroupLLC Dec. 12 at 6:42 PM

0 · Reply

zcurrency Dec. 12 at 1:06 AM

$MNMD

0 · Reply

a_rational_investor Dec. 12 at 12:02 AM

$MNMD typical AH drop for people to load up

0 · Reply

Rocketzz Dec. 11 at 5:44 PM

$MNMD

0 · Reply

brunoq14 Dec. 11 at 5:20 PM

$MNMD The first P3 coming up for MNMD in H1 2026 is GAD, where they got breakthrough status in P2.

0 · Reply

Joe_Twit Dec. 11 at 3:35 PM

$CYBN anybody know what's going on here? It feels like $CYBN is getting ready to run. The price-per-pound for premium IP beats $MNMD and $CMPS IMO

0 · Reply

VinceJ13 Dec. 11 at 12:35 PM

$IXHL it’s crazy to me that a stock like $MNMD can make it into Russel 2k & 3k without revenue or a drug even produced yet & sit @ $12 while we fight tooth and nail to regain compliance. Just goes to show revenue is Not a necessity to be out of penny land, just need more institutional attention 🙏 hopefully Dubai helps bring that.

0 · Reply

MoneyGroupLLC Dec. 10 at 3:53 PM

Enter: $MNMD Calls Strike Price: $13 Expiry Date: JAN 16 2026 Buy in Price: $0.85 - $1.30 Sell Price: $1.31 Profit : +54% (Turn every $1 into $1.54) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MichaelNaussCMT Dec. 10 at 3:45 PM

$MNMD $CMPS 50 easy 100 hard but doable with time

3 · Reply

mora9127 Dec. 10 at 3:38 PM

$MNMD Any realistic chance this can hit $100? Is $CMPS the better play in this sector?

0 · Reply

MichaelNaussCMT Dec. 9 at 11:49 PM

$MNMD $OWLT $OSCR is my next idea. As long as we are holding 16.5 on a weekly closing basis. We have a binary event coming with ACA arguments. If we get pass that and this thing breaks $25 which it has battled for a while I think it could jump to $50 pretty quick using the same target logic. And since we are wrong if we trade down to the 13s the risk reward is nuts. Just like it was with OWLT

2 · Reply

MichaelNaussCMT Dec. 9 at 10:20 PM

$MNMD $OWLT thanks

0 · Reply

Chukt22 Dec. 9 at 9:18 PM

$OWLT @MichaelNaussCMT been following this one since we’re both big $MNMD bulls and saw your post on this one. Great call. Didn’t see the attraction but can’t argue with the results. 👏🏻

0 · Reply

MichaelNaussCMT Dec. 9 at 3:40 PM

$MNMD 13 is a brick wall for this thing

1 · Reply

MoneyGroupLLC Dec. 9 at 2:39 PM

Enter: $MNMD Calls Strike Price: $13 Expiry Date: JAN 16 2026 Buy in Price: $1.30 - $1.60 Sell Price: $2.15 Profit : +65% (Turn every $1 into $1.65) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Market Cap	1.19B
Revenue (ttm)	0.00
Net Income (ttm)	-108.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	1,908,600
Avg Vol	1,876,046
Day's Range	N/A - N/A
Shares Out	98.51M
Stochastic %K	28%
Beta	2.57
Analysts	Strong Sell
Price Target	$25.64